Carmland Malin Erika, Kreutzfeldt Melissa Dall, Holbech Jakob Vormstrup, Brask-Thomsen Peter Kolind, Krøigård Thomas, Hansen Peter Nørregaard, Tankisi Hatice, Jensen Troels Staehelin, Bach Flemming Winther, Sindrup Søren Hein, Finnerup Nanna Brix
Danish Pain Research Center, Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark.
Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.
Eur J Pain. 2024 Jan;28(1):105-119. doi: 10.1002/ejp.2165. Epub 2023 Aug 11.
Neuropathic pain is common and difficult to treat. The sodium channel blocker lacosamide is efficacious in animal models of pain, but its effect on neuropathic pain in humans is inconclusive.
In a multicentre, randomized, double-blinded placebo-controlled phenotype stratified trial, we examined if lacosamide produced better pain relief in patients with the irritable nociceptor phenotype compared to those without. The primary outcome was the change in daily average pain from baseline to last week of 12 weeks of treatment. Secondary and tertiary outcomes included pain relief, patient global impression of change and presence of 30% and 50% pain reduction.
The study was prematurely closed with 93 patients included and 63 randomized to lacosamide or placebo in a 2:1 ratio, of which 49 fulfilled the per protocol criteria and was used for the primary objective. We did not find a better effect of lacosamide in patients with the irritable nociceptor phenotype, the 95% CI for the primary objective was 0.41 (-1.2 to 2.0). For all patients randomized, lacosamide had no effect on the primary outcome, but significantly more patients were responders to lacosamide than during placebo, with an NNT of 4.0 (95% CI 2.3-16.1) and 5.0 (95% CI 2.8-24.5) for 30% and 50% pain reduction respectively. We did not identify any predictors for response. Lacosamide was generally well tolerated.
We could not confirm that lacosamide was more efficacious in patients with the irritable nociceptor type, but the study was prematurely closed, so we cannot exclude a small difference.
Treatment of neuropathic pain is often a trial and error process. Little is known about which patient benefit from which kind of medication. The sodium channel blocker lacosamide shows variable effect on neuropathic pain. Pain sensory phenotype, as defined by quantitative sensory testing, did not predict response to treatment with lacosamide.
神经性疼痛很常见且难以治疗。钠通道阻滞剂拉科酰胺在动物疼痛模型中有效,但其对人类神经性疼痛的影响尚无定论。
在一项多中心、随机、双盲、安慰剂对照的表型分层试验中,我们研究了与无易激惹伤害感受器表型的患者相比,拉科酰胺对有该表型的患者是否能产生更好的疼痛缓解效果。主要结局是从基线到治疗12周最后一周的每日平均疼痛变化。次要和三级结局包括疼痛缓解、患者总体变化印象以及疼痛减轻30%和50%的情况。
该研究提前结束,共纳入93例患者,63例按2:1比例随机分配接受拉科酰胺或安慰剂治疗,其中49例符合方案标准并用于主要目的分析。我们未发现拉科酰胺对有易激惹伤害感受器表型的患者有更好的效果,主要目的分析的95%置信区间为0.41(-1.2至2.0)。对于所有随机分组的患者,拉科酰胺对主要结局无影响,但与安慰剂相比,对拉科酰胺有反应的患者显著更多,疼痛减轻30%和50%的所需治疗人数分别为4.0(95%置信区间2.3 - 16.1)和5.0(95%置信区间2.8 - 24.5)。我们未确定任何反应预测因素。拉科酰胺总体耐受性良好。
我们无法证实拉科酰胺对有易激惹伤害感受器类型的患者更有效,但该研究提前结束,因此我们不能排除存在微小差异的可能性。
神经性疼痛的治疗通常是一个反复试验的过程。对于哪种患者能从哪种药物中获益知之甚少。钠通道阻滞剂拉科酰胺对神经性疼痛的效果不一。通过定量感觉测试定义的疼痛感觉表型并不能预测对拉科酰胺治疗的反应。